1 INTRODUCTION
1.1 DEFINITION
1.2 SCOPE OF STUDY
1.2.1 RESEARCH OBJECTIVE
1.2.2 ASSUMPTIONS & LIMITATIONS
1.2.2.1 ASSUMPTIONS
1.2.2.2 LIMITATIONS
1.3 MARKET STRUCTURE
2 RESEARCH METHODOLOGY
2.1 RESEARCH PROCESS:
2.2 PRIMARY RESEARCH
2.3 SECONDARY RESEARCH
3 MARKET DYNAMICS
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 MACROECONOMIC INDICATORS
4 MARKET FACTOR ANALYSIS
4.1 PORTERS FIVE FORCES MODEL
4.2 BARGAINING POWER OF SUPPLIERS
4.3 BARGAINING POWER OF BUYERS
4.4 THREAT OF NEW ENTRANTS
4.5 THREAT OF SUBSTITUTES
4.6 INTENSITY OF RIVALRY
5 GLOBAL MONOCLONAL ANTIBODY THERAPY MARKET, BY SOURCE
5.1 RECOMBINANT
5.2 CHIMERIC
5.3 HUMANIZED
5.4 HUMAN
5.5 OTHER
6 GLOBAL MONOCLONAL ANTIBODY THERAPY MARKET, BY APPLICATION
6.1 DIAGNOSTIC TEST
6.2 ANALYTICAL AND CHEMICAL USES
6.3 CANCER TREATMENT
6.4 AUTOIMMUNE DISEASES
6.5 HEMATOLOGICAL DISORDERS
6.6 OTHERS
7 GLOBAL MONOCLONAL ANTIBODY THERAPY MARKET, BY END USER
7.1 HOSPITALS
7.2 CLINICS
7.3 RESEARCH LABORATORIES
7.4 OTHERS
8. GLOBAL MONOCLONAL ANTIBODY THERAPY MARKET, BY REGION
8.1 AMERICA
8.1.1 INTRODUCTION
8.2 EUROPE
8.2.1 INTRODUCTION
8.3 ASIA-PACIFIC
8.3.1 INTRODUCTION
8.4 MIDDLE EAST & AFRICA
8.4.1 INTRODUCTION
9 COMPETITIVE LANDSCAPE
9.1 MAJOR STRATEGIES ADOPTED BY MARKET PLAYERS
9.1.1 STRATEGIC PARTNERSHIP
9.1.2 MERGER & ACQUISITION
10 COMPANY PROFILE
10.1 ABBVIE INC.
10.1.1 OVERVIEW
10.1.2 PRODUCT OVERVIEW
10.1.3 FINANCIALS
10.1.4 KEY DEVELOPMENTS
10.2 AMGEN INC
10.2.1 OVERVIEW
10.2.2 PRODUCT OVERVIEW
10.2.3 FINANCIALS
10.2.4 KEY DEVELOPMENTS
10.3 GLAXOSMITHKLINE PLC
10.3.1 OVERVIEW
10.3.2 PRODUCT OVERVIEW
10.3.3 FINANCIALS
10.3.4 KEY DEVELOPMENT
10.4 MERCK KGAA
10.4.1 OVERVIEW
10.4.2 PRODUCT OVERVIEW
10.4.3 FINANCIALS
10.4.4 KEY DEVELOPMENTS
10.5 NOVARTIS AG
10.5.1 OVERVIEW
10.5.2 PRODUCT OVERVIEW
10.5.3 FINANCIALS
10.5.4 KEY DEVELOPMENTS
10.6 OTHERS
List of Tables
TABLE 1 GLOBAL MONOCLONAL ANTIBODY THERAPY MARKET, BY SOURCE, 2020-2027 (USD MILLION)
TABLE 2 GLOBAL MONOCLONAL ANTIBODY THERAPY MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 3 GLOBAL MONOCLONAL ANTIBODY THERAPY MARKET, BY END USER, 2020-2027 (USD MILLION)
TABLE 4 GLOBAL MONOCLONAL ANTIBODY THERAPY MARKET, BY REGION, 2020-2027 (USD MILLION)
List of Figures
FIGURE 1 RESEARCH PROCESS
FIGURE 2 PORTERS FIVE FORCES MODEL
FIGURE 3 GLOBAL MONOCLONAL ANTIBODY THERAPY MARKET, BY SOURCE
FIGURE 4 GLOBAL MONOCLONAL ANTIBODY THERAPY MARKET, BY APPLICATION
FIGURE 5 GLOBAL MONOCLONAL ANTIBODY THERAPY MARKET, BY END USER
FIGURE 6 GLOBAL MONOCLONAL ANTIBODY THERAPY MARKET, BY REGION
FIGURE 7 GLOBAL MONOCLONAL ANTIBODY THERAPY MARKET: COMPANY SHARE ANALYSIS, 2020 (%)
Research Analyst Level I He is an extremely curious individual currently working in healthcare and medical devices domain. kinjoll is comfortably versed in data centric research backed by healthcare educational background. he leverages extensive data mining and analytics tools such as primary and secondary research, statistical analysis, machine learning, data modelling. his key role also involves technical sales support, client interaction and project management within the healthcare team. lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
